--------------------------------------------------------------------------------

                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                   -----------
                               Amendment No. 2 to
                                   FORM 10-KSB

/X/  ANNUAL REPORT  PURSUANT TO SECTION 13 OR 15(d) OF THE  SECURITIES  EXCHANGE
     ACT OF 1934 For the fiscal year ended December 31, 2004

/ /  TRANSITION  REPORT  PURSUANT  TO  SECTION  13 OR  15(d)  OF THE  SECURITIES
     EXCHANGE ACT OF 1934

                  For the transition period from _____ to_____
                         Commission File Number: 0-49666

                         TIENS BIOTECH GROUP (USA), INC.
              (Exact name of small business issuer in its charter)

           Delaware                                              75-2926439
           --------                                              ----------
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                              Identification No.)

           No. 6, Yuanquan Rd.
    Wuqing New Tech Industrial Park
             Tianjin, China                                        301700
----------------------------------------                           ------
(Address of principal executive offices)                         (Zip Code)

                 Registrant's Telephone Number: 86-22-8213-7658

                                       N/A
                            (Former Name and Address)

           Securities registered under 12(b) of the Exchange Act: None

             Securities registered under 12(g) of the Exchange Act:
                         Common Stock, par value $0.001

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. YES /X/ NO / /

Check if there is no disclosure of delinquent  filers in response to Item 405 of
Regulation S-B contained in this form, and no disclosure  will be contained,  to
the  best  of  registrant's   knowledge,  in  definitive  proxy  or  information
statements  incorporated  by  reference  in Part III of this Form  10-KSB or any
amendment to this Form 10-KSB. / /

Issuer's revenues for its most recent fiscal year: $  58,910,532  .
                                                    --------------

The aggregate market value of 3,503,586 the voting and non-voting  common equity
held by  non-affiliates of the Registrant as of March 29, 2005 was approximately
$  17,167,571.40,  based  upon the  closing  sale  price of $ 4.90 per  share as
reported by The Over the Counter Bulletin Board on such date.

There were  71,333,586  shares of the  Company's  common  stock  outstanding  on
September 15, 2005.

Transitional Small Business Disclosure Format (check one): YES / / NO /X/

DOCUMENTS INCORPORATED BY REFERENCE - None


<PAGE>

                                EXPLANATORY NOTE

     We are filing this  Amendment No. 2 to our Annual Report on Form 10-KSB for
the fiscal year ended December 31, 2004 to amend our  disclosure  under Part II,
Item 8A. We filed  Amendment No. 1 to our Annual Report on Form 10-KSB on August
11, 2005. Except as specifically  referenced herein, this Amendment No. 2 to our
Annual Report on Form 10-KSB/A does not reflect any event  occurring  subsequent
to March 31, 2005, the filing date of the original report.

PART II

ITEM 8A. CONTROLS AND PROCEDURES

Under the supervision and with the  participation  of management,  including our
chief  executive  officer  and the chief  financial  officer,  we  conducted  an
evaluation of the  effectiveness  of the design and operation of our  disclosure
controls and  procedures,  as defined in Rules 13a-15(e) and 15d-15(e) under the
Securities  Exchange  Act of 1934,  as of the end of the period  covered by this
report (the "Evaluation  Date").  Based on this evaluation,  our chief executive
officer and chief financial officer concluded as of the Evaluation Date that our
disclosure  controls  and  procedures  were  effective  such  that the  material
information  required to be included in our Securities  and Exchange  Commission
("SEC") reports is recorded, processed,  summarized and reported within the time
periods specified in SEC rules and forms relating to our company,  including our
consolidating  subsidiaries,  and was made known to them by others  within those
entities, particularly during the period when this report was being prepared.

Additionally,  there  were no  significant  changes  in the  Company's  internal
controls or in other  factors that could  significantly  affect  these  controls
subsequent  to the  Evaluation  Date.  We have not  identified  any  significant
deficiencies  or material  weaknesses  in our internal  controls,  and therefore
there were no corrective actions taken.

PART III

ITEM 13. EXHIBITS AND REPORTS

Exhibits

-------------- -----------------------------------------------------------------

Exhibit No.    Description
-------------- -----------------------------------------------------------------

2.1            Agreement  and Plan of  Reorganization,  as amended,  dated as of
               August 22, 2003, by and among Strategika,  Tianshi  International
               and the Stockholders of Tianshi International (1)
-------------- -----------------------------------------------------------------

3.1            Certificate of Incorporation of MIA Acquisition Corp. (2)
-------------- -----------------------------------------------------------------

3.2            By-laws of MIA Acquisition Corp (2)
-------------- -----------------------------------------------------------------

3.3            Certificate of Amendment to Certificate of  Incorporation  of MIA
               Acquisition Corp. changing the company's name to Strategika (2)
-------------- -----------------------------------------------------------------

4.1            Specimen Stock Certificate (2)
-------------- -----------------------------------------------------------------

10.1           Stock Purchase Agreement, dated February 11, 2002, by and between
               Rene Larrave and MIA Acquisition Corp. (2)
-------------- -----------------------------------------------------------------
14             Code of Ethics (1)
-------------- -----------------------------------------------------------------

23.1           Consent of Independent  Accountants,  Moore Stephens Wurth Frazer
               and Torbet, LLP (3)
-------------- -----------------------------------------------------------------

31.1*          Certification of the Chief Executive  Officer pursuant to Section
               302 of the Sarbanes-Oxley Act of 2002
-------------- -----------------------------------------------------------------

31.2*          Certification of the Chief Financial  Officer and Chief Financial
               Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
-------------- -----------------------------------------------------------------

32.1*          Certification of the Chief Executive  Officer pursuant to Section
               906 of the Sarbanes-Oxley Act of 2002
-------------- -----------------------------------------------------------------

32.2*          Certification of the Chief Financial  Officer pursuant to Section
               906 of the Sarbanes-Oxley Act of 2002
-------------- -----------------------------------------------------------------

*  Filed herewith

(1) Filed as an exhibit to the  Registrant's  Annual Report on Form 10-KSB filed
with the Securities and Exchange  Commission on March 31, 2005 and  incorporated
by reference.

(2) Filed as an exhibit to the Registrant's  Form 10SB filed with the Securities
and Exchange Commission on March 7, 2002 and incorporated by reference.

(3) Filed as an exhibit to the Registrant's Amendment No. 1 to the Annual Report
on Form 10-KSB filed with the Securities  and Exchange  Commission on August 11,
2005 and incorporated by reference.

<PAGE>

                                   SIGNATURES

     In accordance  with Section 13 or 15(d) of the  Securities  Exchange Act of
1934,  the  registrant  has caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                                        TIENS BIOTECH GROUP (USA), INC.


                                        By: /s/ Jinyuan Li
                                           -------------------------------------
                                           Jinyuan Li
                                           Chief Executive Officer and President
                                           (Principal Executive Officer)

Date: September 16, 2005


                                        By: /s/ Wenjun Jiao
                                           -------------------------------------
                                           Wenjun Jiao
                                           Chief Financial Officer
                                           (Principal Accounting Officer)

Date: September 16, 2005